BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Biopta Closes £900,000 Investment To Grow Its Drug Development Services


12/4/2008 12:57:12 PM

Glasgow, UK, 4th December 2008: Biopta Ltd, the human tissue-based contract research organisation, today announced that it had completed a £900,000 funding round from both new and existing investors. Biopta is part of the rapidly growing move towards outsourced drug development and offers services using ethically donated residual human tissue from surgery as a test system for new pharmaceutical compounds. Dr David Bunton, Chief Operating Officer and co-founder of Biopta said “because we use human tissues so rapidly after surgery, the information about drug safety and effectiveness that we generate is the closest possible alternative to a clinical trial”. Biopta’s turnover has doubled in each of the past three years and is looking forward to more significant growth in the years ahead.

The investment will allow Biopta to greatly expand the range of services it offers and to grow its team of scientists, including the appointment of a Head of R&D who will lead the development of Biopta’s new range of human tissue based services. Claire Jenkins, Sales Director at Biopta said ”currently we are only scratching the surface of the human tissue research market and this investment will let us meet the demands of new and existing clients. As the only European human tissue based company with GLP (Good Laboratory Practice) accreditation we have a lead in the market”.

Investment in this round includes funding from Braveheart Investment Group and Scottish Enterprise’s Scottish Co-Investment Fund – both of which have previously invested in Biopta. Significant new investors have also come on board including Borders-based angel group, TriCap and private individuals. Elaine Ferguson, Finance Director at Biopta said ‘‘this investment is a great vote of confidence from both existing investors and new investors who recognise that Biopta has developed a strong brand as experts in human tissue research in an emerging market”

About Biopta

Biopta, founded in 2002 as spin-out of Glasgow Caledonian University, is a unique early development in vitro CRO (contract research organisation), providing novel services in fresh ex vivo human tissues to global pharmaceutical and biotechnology companies.

Biopta’s services improve the predictability and efficiency of drug development by providing ’Good Laboratory Practice’-compliant safety and efficacy services in ethically-donated human tissues. These highly predictive assays bridge the gap between cell-based screening and animal in vivo studies by providing powerful human data much earlier in the development process. Biopta aims to reduce the risk of late stage drug failures and add value to early stage compounds. For more information on Biopta, please visit www.biopta.com.

Read at BioSpace.com

Biopta
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES